Zum Artikel

Dr. Christian Kannemeier Senior Investment Manager

Dr. Christian KannemeierSenior Investment Manager

Dr. Christian Kannemeier

Senior Investment Manager

About me

Team investment comittee, Investment comittee, Life Sciences & Chemistry
at HTGF since 2023

CV

Christian joined HTGF’s Life Science team as a Senior Investment Manager in August 2023. Christian studied biology in Giessen and received his PhD in cell biology/biochemistry in collaboration with a pharmaceutical company in Marburg. Subsequently, he did postdoctoral research at the Scripps Research Institute in San Diego in the field of tumor transformation.

During his 11-year tenure with two start-up companies in California and Wisconsin, Christian led projects on the generation, differentiation, and application of human stem cells in various disease models in the drug discovery process. He has led projects on high throughput human stem cell manufacturing and the introduction of new cell-based products.

In 2018, he moved to Evotec in Hamburg, Germany, where he was able to further advance the application of stem cells in drug discovery and learn about the drug discovery processes in detail.

Social Media & contact

My success stories in the HTGF portfolio

12 of 500 Companies
2025

mo:re

R&D Tools

mo:re has developed a groundbreaking lab platform, combining automation and software for planning, executing, and analysis of cell culture studies. The user-friendly platform aims to simplify cell culture, making organoids …

To the complete profileof mo:re
2024

Refoxy Pharma

Rejuvenation

Refoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. Refoxy’s discovery platform, F.act finder (FOXO activator …

To the complete profileof Refoxy Pharma
2024

TQ Therapeutics

Gene Therapy

TQ Therapeutics GmbH (Martinsried, Germany) is a biotechnology company dedicated to advancing the field of cellular therapies through innovative technologies. The company’s mission is to develop a transformative cell processing …

To the complete profileof TQ Therapeutics
2019

innerspace

EdTech & HR-Solutions

Innerspace develops novel, psychologically based training solutions for highly critical applications in the life science industry. Cleanroom operators are comprehensively prepared for the key moments of their work using the …

To the complete profileof innerspace
2019

Vacis

Cardiovascular Devices

VACIS is the leading tissue engineering company for body-own blood vessels. The VACIS technology uses a synthetic rod which induces the formation of a new fully functional blood vessel providing …

To the complete profileof Vacis
2015

heartbeat medical

Digital Health

heartbeat ONE provides a streamlined patient management tool for health care facilities of all sizes. It offers intelligent evaluations of diagnostics and treatment methods. It supports the preparation, documentation and …

To the complete profileof heartbeat medical
2012

AudioCure

Hearing loss

AudioCure Pharma is an innovative clinical-stage pharmaceutical company focused on developing treatments for audiological and neurological disorders with a high unmet medical need. Our small molecules have shown Proof-of-Principle in …

To the complete profileof AudioCure

Guided to exit

12 of 500 Companies

Recent posts

Last update 3 days ago
Zum Artikel

News

26. March 2025

mo:re launches lab platform to set a new standard in animal-free drug development

Zum Artikel

News

16. February 2025

InfectoPharm invests in AudioCure to advance innovative hearing loss therapy

Zum Artikel

News

4. December 2024

Refoxy Pharmaceuticals raises €9.1 million to progress its novel FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis

Zum Artikel

News

1. February 2024

Fresh Growth Capital: Innerspace secures € 5.7 Million for Further Expansion to the USA